Original Publication Date: 1 February, 2015
Publication / Source: Lung Cancer Management
Authors: Antonio Rossi & Domenico Galetta
Every patient affected by advanced and recurrent NSCLC, despite modest outcome benefits from first-line therapy, experiences disease progression and requires salvage therapy. In second-line settings, only a small percentage of patients, in other words, those with oncogene-addicted NSCLC, can benefit from specific inhibitors if still not received at first line, and another small percentage may be enrolled in clinical trials.